Ion Exchange Q1 FY27: Revenue Up, Margins Under Pressure as Legacy Projects and Roha Costs Bite

Ion Exchange (India) Limited reported a strong start to FY27 in terms of revenue, but profitability remained under stress. In Q1 FY27, consolidated operating income rose to INR 700.5 crore, up 20.1% year-on-year. The quarter, however, reflected sharp margin compression with EBITDA of INR 31.8 crore and EBITDA margin of 4.54%. Profit after tax was INR 3.1 crore with a PAT margin of 0.44%.

Alongside the quarterly results, management introduced a major change in reporting. The earlier “Engineering” segment has been split into Treatment Solutions, Industrial Products, and Lifecycle Services. Chemicals has been renamed Specialty Chemicals, while Consumer Products remains a separate segment. Management’s stated objective is to give investors more transparency on where growth and profitability are coming from, especially because products and services were previously embedded within Engineering.

A new segment lens: what it reveals in Q1 FY27

The reclassification makes the contrast within the portfolio more visible. Treatment Solutions, which includes EPC-style water and wastewater projects, continues to face pressure from legacy contracts. Industrial Products and Lifecycle Services, which are closer to repeatable and product-led revenues, showed better operating performance. Specialty Chemicals grew strongly on revenue but saw a sharp decline in EBIT, with management citing geopolitical disruption and cost impact from the Roha facility.

On an operational front, the company pointed to resumed dispatches to the GCC, and reiterated its focus on overseas markets. It also disclosed an orderbook (for Treatment Solutions, Industrial Products, and Lifecycle Services) of around INR 2,473 crore as of 30 June 2026 and a bid pipeline of about INR 9,777 crore. A separate contract win of USD 52.83 million from Hyundai Engineering and Construction was noted as being awarded after the quarter.

Segment performance: growth everywhere, profitability uneven

Treatment Solutions: growth, but dragged by legacy execution

Treatment Solutions revenue increased 14% year-on-year to INR 209.9 crore in Q1 FY27. But the segment reported an EBIT loss of INR 17.4 crore. Both the investor presentation and conference call repeatedly linked this to legacy projects and cost overruns, with management emphasizing that some large contracts have taken longer and impacted profitability.

Management also clarified that the UP project’s pace is tied to government fund flows, and that execution is being calibrated to avoid building receivables. It stated that the UP project will likely spill into the next financial year, and it did not reaffirm any near-term completion commitment.

Industrial Products: margins move sharply higher

Industrial Products reported revenue of INR 105.1 crore, up 14% year-on-year. The segment’s EBIT rose to INR 12.5 crore, and EBIT margin improved significantly to 11.89% from 5.53% in Q1 FY26. Management attributed this to strong performance in standard water treatment solutions and membranes.

The company cited ongoing investments for growth, including expansion for UF membrane manufacturing and enhanced capacity for standard plants and systems, alongside an increasing overseas reach.

Lifecycle Services: steady scale-up, with a focus on O&M and consumables

Lifecycle Services reported revenue of INR 71.6 crore, up 28% year-on-year, and EBIT of INR 7.1 crore. EBIT margin moderated slightly to 9.92% from 10.55% due to higher input costs.

In the call, management positioned services as a key pillar for repeatable and more predictable revenues. It referenced a strategic shift towards models like BOO, BOOT, rentals and water-as-a-service, while also cautioning that some concession models can introduce different capital pressures.

Specialty Chemicals: revenue up, EBIT down sharply

Specialty Chemicals revenue grew 21% year-on-year to INR 229.7 crore, but EBIT declined to INR 22.3 crore from INR 46.3 crore in Q1 FY26. Management cited geopolitical factors and higher costs tied to the Roha facility, which was commissioned in FY26 and is still stabilizing.

In a Q&A disclosure, the CFO stated that the impact of Roha on the chemical segment margin was approximately 6% in the quarter. Management also indicated that last year’s quarter included foreign exchange gains, which did not repeat in Q1 FY27, and that there can be a lag in passing input cost increases to customers.

Consumer Products: strong growth, profitability still near break-even

Consumer Products revenue increased 33% year-on-year to INR 112.4 crore. The segment remained loss-making at the EBIT level, though the loss narrowed modestly versus the prior year quarter. Management’s stated near-term goal is to achieve break-even in the Consumer Products business during the current financial year.

Roha and overseas markets: the strategic bet that must start delivering

The Roha investment remains central to the Ion Exchange story. Management described Roha as addressing capacity constraints at the older Ankleshwar resin facility, and stated that post Phase I expansion and further Phase II plus debottlenecking, total resin capacity across Roha and Ankleshwar is expected to reach roughly five times the original Ankleshwar baseline.

In the earnings call, management also reiterated that a significant portion of Roha utilization is expected to come from overseas markets, including North America, where product certifications are necessary. It noted that Water Quality Association certification is a required step to sell resins in the Americas market and positioned this as part of a broader global go-to-market approach, which also includes the appointment of regional leaders across key geographies.

However, management acknowledged that Roha utilization in the first four months of FY27 has been softer than expected. It stated it is still working toward the previously communicated utilization target, and expects to provide a clearer update after the second quarter.

Takeaways for investors: clarity is improving, but execution remains the swing factor

Ion Exchange entered FY27 with solid top-line momentum and double-digit segment revenue growth across all five segments. The quarter still underlined that profitability recovery depends on two execution variables: the pace at which legacy Treatment Solutions projects stop dragging EBIT, and the speed at which Roha capacity stabilizes and ramps.

The new segment reporting is a meaningful step. It highlights that Industrial Products and Lifecycle Services are showing healthier unit economics and could structurally improve the group’s mix over time. For now, the near-term narrative remains one of transition: improving transparency, building overseas scale, and grinding through legacy project headwinds while investments like Roha start translating into stable margins.